Biology Reference
In-Depth Information
Newton R, Leigh R, Giembycz MA (2010) Pharmacological strategies for improving the efficacy
and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol Ther 125:
286-327
Nie M, Corbett L, Knox AJ, Pang L (2005a) Differential regulation of chemokine expression
by peroxisome proliferator-activated receptor
g
agonists: interactions with glucocorticoids and
b
2
-agonists. J Biol Chem 280:2550-2561
Nie M, Knox AJ, Pang L (2005b)
b
2
-Adrenoceptor agonists, like glucocorticoids, repress eotaxin
gene transcription by selective inhibition of histone H4 acetylation. J Immunol 175:478-486
O'Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, Balter M, Ford G,
Gervais A, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N (2008) Canadian
Thoracic Society recommendations for management of chronic obstructive pulmonary disease
- 2008 update - highlights for primary care. Can Respir J 15(Suppl A):1A-8A
Ogawa R, Streiff MB, Bugayenko A, Kato GJ (2002) Inhibition of PDE4 phosphodiesterase
activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and
p21
(WAF1/CIP1)
proteins in human acute lymphoblastic leukemia cells. Blood 99:3390-3397
Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, Hoffmann A, Subramaniam S,
David M, Rosenfeld MG, Glass CK (2005) Molecular determinants of crosstalk between
nuclear receptors and toll-like receptors. Cell 122:707-721
Oxford AW, Jack D (2000) Derivatives of pyrimidino[6,1-
a
]isoquinoline-4-one. Verona Pharma,
WO 00/58308
Pages L, Gavalda A, Lehner MD (2009) PDE4 inhibitors: a review of current developments
(2005-2009). Expert Opin Ther Pat 19:1501-1519
Pang L, Knox AJ (2000) Synergistic inhibition by
b
2
-agonists and corticosteroids on tumor
necrosis factor-
a
-induced interleukin-8 release from cultured human airway smooth-muscle
cells. Am J Respir Cell Mol Biol 23:79-85
Parrella E, Gianni' M, Cecconi V, Nigro E, Barzago MM, Rambaldi A, Rochette-Egly C, Terao M,
Garattini E (2004) Phosphodiesterase IV inhibition by piclamilast potentiates the cytodiffer-
entiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the
retinoic acid signaling pathways. J Biol Chem 279:42026-42040
Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A (1997)
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and
Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337:
1405-1411
Postma DS, Kerstjens HA (1998) Characteristics of airway hyperresponsiveness in asthma and
chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158:S187-S192
Prasad S, Wilkinson J, Gatzoulis MA (2000) Sildenafil in primary pulmonary hypertension.
N Engl J Med 343:1342
Pratt WB, Galigniana MD, Harrell JM, DeFranco DB (2004) Role of hsp90 and the hsp90-binding
immunophilins in signalling protein movement. Cell Signal 16:857-872
Rangarajan PN, Umesono K, Evans RM (1992) Modulation of glucocorticoid receptor function by
protein kinase A. Mol Endocrinol 6:1451-1457
Reisman D, Thompson EA (1995) Glucocorticoid regulation of cyclin D3 gene transcription and
mRNA stability in lymphoid cells. Mol Endocrinol 9:1500-1509
Roberts JA, Bradding P, Britten KM, Walls AF, Wilson S, Gratziou C, Holgate ST, Howarth PH
(1999) The long-acting
b
2
-agonist salmeterol xinafoate: effects on airway inflammation in
asthma. Eur Respir J 14:275-282
Robicsek SA, Blanchard DK, Djeu JY, Krzanowski JJ, Szentivanyi A, Polson JB (1991) Multiple
high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 42:
869-877
Rolan P, Hutchinson M, Johnson K (2009) Ibudilast: a review of its pharmacology, efficacy and
safety in respiratory and neurological disease. Expert Opin Pharmacother 10:2897-2904
Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG,
Beavo JA (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is
